ADMA Biologics (ADMA) Competitors $22.15 +1.24 (+5.93%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$21.86 -0.29 (-1.29%) As of 04/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADMA vs. TEVA, ITCI, SMMT, GMAB, RDY, MRNA, VTRS, QGEN, ASND, and ROIVShould you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. ADMA Biologics vs. Teva Pharmaceutical Industries Intra-Cellular Therapies Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Teva Pharmaceutical Industries (NYSE:TEVA) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Does the MarketBeat Community believe in TEVA or ADMA? Teva Pharmaceutical Industries received 920 more outperform votes than ADMA Biologics when rated by MarketBeat users. However, 72.13% of users gave ADMA Biologics an outperform vote while only 67.82% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes133467.82% Underperform Votes63332.18% ADMA BiologicsOutperform Votes41472.13% Underperform Votes16027.87% Does the media refer more to TEVA or ADMA? In the previous week, Teva Pharmaceutical Industries had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 20 mentions for Teva Pharmaceutical Industries and 17 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.25 beat Teva Pharmaceutical Industries' score of 1.13 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 15 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TEVA or ADMA? Teva Pharmaceutical Industries currently has a consensus target price of $23.43, suggesting a potential upside of 72.46%. ADMA Biologics has a consensus target price of $22.50, suggesting a potential upside of 1.58%. Given Teva Pharmaceutical Industries' higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than ADMA Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals and insiders hold more shares of TEVA or ADMA? 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, TEVA or ADMA? Teva Pharmaceutical Industries has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Is TEVA or ADMA more profitable? ADMA Biologics has a net margin of 17.80% compared to Teva Pharmaceutical Industries' net margin of -9.91%. ADMA Biologics' return on equity of 53.20% beat Teva Pharmaceutical Industries' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-9.91% 42.46% 6.65% ADMA Biologics 17.80%53.20%26.07% Which has preferable valuation and earnings, TEVA or ADMA? ADMA Biologics has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B0.93-$1.64B-$1.45-9.37ADMA Biologics$426.45M12.28-$28.24M$0.8227.01 SummaryADMA Biologics beats Teva Pharmaceutical Industries on 13 of the 19 factors compared between the two stocks. Remove Ads Get ADMA Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADMA vs. The Competition Export to ExcelMetricADMA BiologicsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.24B$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio79.1131.0021.7317.81Price / Sales12.28441.16379.2094.61Price / Cash311.70168.6838.1534.64Price / Book36.923.476.464.00Net Income-$28.24M-$72.06M$3.20B$247.23M7 Day Performance14.23%3.17%2.85%1.45%1 Month Performance20.18%-16.97%-8.55%-6.24%1 Year Performance259.58%-29.07%10.46%0.60% ADMA Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADMAADMA Biologics1.8854 of 5 stars$22.15+5.9%$22.50+1.6%+270.4%$5.24B$426.45M79.11530Options VolumeNews CoveragePositive NewsGap UpTEVATeva Pharmaceutical Industries3.0326 of 5 stars$13.91+0.8%$23.43+68.5%+2.7%$15.77B$16.54B-9.5936,800Analyst DowngradeOptions VolumePositive NewsITCIIntra-Cellular Therapies3.4948 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsSMMTSummit Therapeutics2.6134 of 5 stars$17.29-0.4%$35.40+104.8%+573.6%$12.75B$700,000.00-61.73110News CoverageGMABGenmab A/S4.2091 of 5 stars$18.21-1.0%$41.33+127.0%-33.9%$12.05B$21.53B10.461,660Short Interest ↓Gap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.3519 of 5 stars$12.59+1.8%$17.00+35.1%-6.3%$10.51B$311.31B20.0424,800MRNAModerna4.259 of 5 stars$25.64+2.1%$59.00+130.1%-74.7%$9.91B$3.20B-2.763,900Gap DownVTRSViatris2.9677 of 5 stars$7.61-0.1%$10.50+37.9%-33.9%$9.09B$14.74B-10.2937,000News CoverageQGENQiagen3.483 of 5 stars$40.33+5.4%$47.71+18.3%+7.7%$8.96B$1.98B112.296,030High Trading VolumeASNDAscendis Pharma A/S2.3142 of 5 stars$139.82-2.0%$204.64+46.4%+6.0%$8.49B$363.64M-19.691,017News CoveragePositive NewsGap DownROIVRoivant Sciences2.6317 of 5 stars$9.26-2.2%$17.50+89.1%-7.2%$6.60B$122.59M-61.70860Positive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies TEVA Alternatives ITCI Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives ASND Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADMA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADMA Stock Free ADMA Stock Alerts